Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.92

€7.92

-1.740%
-0.14
-1.740%
€30.91
 
03.07.26 / Frankfurt WKN: A0NBFF / Symbol: OMER / Name: Omeros / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for Omeros

sharewise wants to provide you with the best news and tools for Omeros, so we directly link to the best financial data sources.

News

Omeros Q1 Earnings Call Highlights
Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/2d10dfb318519977a677bcb00f3da6d28e64e4b0-1200x800.png?w=800&q=75&fit=max&auto=format
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique